An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?
Open Access
- 1 June 2018
- journal article
- research article
- Published by Elsevier BV in Health Policy
- Vol. 122 (6), 607-613
- https://doi.org/10.1016/j.healthpol.2018.04.008
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
This publication has 35 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Real Option Value and Path Dependence in Oncology InnovationInternational Journal of the Economics of Business, 2011
- Economic Burden for Informal Caregivers of Lung and Colorectal Cancer PatientsThe Oncologist, 2010
- An economic evaluation of the war on cancerJournal of Health Economics, 2010
- Costing and Perspective in Published Cost-Effectiveness AnalysisMedical Care, 2009
- How Should We Value Lives Lost to Cancer?JNCI Journal of the National Cancer Institute, 2008
- Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish populationMutation research. Reviews in mutation research, 2006
- Costs of Health Care Administration in the United States and CanadaThe New England Journal of Medicine, 2003
- Willingness to Pay for a Quality-adjusted Life YearMedical Decision Making, 2000
- Foundations of Cost-Effectiveness Analysis for Health and Medical PracticesThe New England Journal of Medicine, 1977